<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34454204</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-6968</ISSN><JournalIssue CitedMedium="Internet"><Volume>208</Volume><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Clinical neurology and neurosurgery</Title><ISOAbbreviation>Clin Neurol Neurosurg</ISOAbbreviation></Journal><ArticleTitle>Assessment of diagnostic potential of some circulating microRNAs in Amyotrophic Lateral Sclerosis Patients, an Egyptian study.</ArticleTitle><Pagination><StartPage>106883</StartPage><MedlinePgn>106883</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clineuro.2021.106883</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0303-8467(21)00412-1</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Numerous studies have been carried out to identify the role of microRNA (miRNA) as potential biomarkers for many diseases including amyotrophic lateral sclerosis (ALS). The aim of this study was to explore the circulating levels of some miRNAs in cohort of Egyptian ALS patients in an attempt to correlate the selected miRNA profiles with disease progression.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirty ALS patients and 20 age and sex matched healthy controls were enrolled. Circulating miRNA levels were determined in venous blood samples, collected on EDTA, from all the study subjects. The selection of miRNA species (miR-206, miR-142-3p, miR-143-3p, miR-181a-5p, miR-106b-3p, miR-4516 and Let7f-5p) was based on their involvement in the pathophysiology of ALS and was further confirmed by data mining of specific miRNA databases (miRBase and miRDB).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">As compared to the control group, significant consistent upregulation was found in the levels of miR-206, miR-143-3p and to a lesser extent in miR-142-3p. An elevation trend, although not significant, was also found in the levels of miR-181a-5p, miR-106b-3p, and miR-4516. Interestingly, we found that the levels of miR-142-3p were elevated in familial cases, while that of miR-4516 were significantly increased in sporadic cases. Furthermore, the levels of Let7f-5p, although were generally lowered in ALS patients but were also decreased in familial cases as well as in spinal onset ALS as compared to bulbar onset.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This is the first study investigating miRNA profiles in Egyptian ALS patients. We found that some miRNAs are significantly altered in ALS patients, and some may be used to distinguish familial and sporadic cases and bulbar and spinal onset. Larger study is needed, in which we will conduct a correlation of miRNA levels against variations in disease onset, progression as well as systemic inflammatory responses and the extent of neuromuscular involvement in Egyptian ALS patients in an attempt to identify environmental/occupational risk factors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soliman</LastName><ForeName>Radwa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neuromuscular Unit, Neurology and Psychiatry Department, Faculty of Medicine Ain Shams University, Cairo 11566, Egypt. Electronic address: radwasoliman@med.asu.edu.eg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mousa</LastName><ForeName>Nahla O</ForeName><Initials>NO</Initials><AffiliationInfo><Affiliation>Biotechnology Department, Basic and Applied Sciences Institute, Egypt-Japan University of Science and Technology, Borg Al Arab 21934, Egypt; Biotechnology Program, Chemistry Department, Faculty of Science, Cairo University, Cairo 12613, Egypt. Electronic address: nahlaosama@aucegypt.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rashed</LastName><ForeName>Hebatallah R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Neuromuscular Unit, Neurology and Psychiatry Department, Faculty of Medicine Ain Shams University, Cairo 11566, Egypt. Electronic address: rashedheba@med.asu.edu.eg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moustafa</LastName><ForeName>Ramez R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Neuromuscular Unit, Neurology and Psychiatry Department, Faculty of Medicine Ain Shams University, Cairo 11566, Egypt. Electronic address: ramezrm@med.asu.edu.eg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamdi</LastName><ForeName>Nabila</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Molecular Pathology Unit, German University in Cairo (GUC), Cairo, Egypt. Electronic address: nabila.hamdi@guc.edu.eg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osman</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biotechnology Department, Basic and Applied Sciences Institute, Egypt-Japan University of Science and Technology, Borg Al Arab 21934, Egypt; Biochemistry Department, Faculty of Science, Ain Shams University, Cairo 11566, Egypt. Electronic address: ahmed.osman@ejust.edu.eg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fahmy</LastName><ForeName>Nagia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neuromuscular Unit, Neurology and Psychiatry Department, Faculty of Medicine Ain Shams University, Cairo 11566, Egypt. Electronic address: dr.nagiafahmy@med.asu.edu.eg.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Clin Neurol Neurosurg</MedlineTA><NlmUniqueID>7502039</NlmUniqueID><ISSNLinking>0303-8467</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074166">Circulating MicroRNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074166" MajorTopicYN="N">Circulating MicroRNA</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004534" MajorTopicYN="N" Type="Geographic">Egypt</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">miR-142-3p</Keyword><Keyword MajorTopicYN="N">miR-143-3p</Keyword><Keyword MajorTopicYN="N">miR-206</Keyword><Keyword MajorTopicYN="N">miR-4516</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>28</Day><Hour>20</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34454204</ArticleId><ArticleId IdType="doi">10.1016/j.clineuro.2021.106883</ArticleId><ArticleId IdType="pii">S0303-8467(21)00412-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>